High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.

Abstract:

BACKGROUND: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects. METHODS: This analysis used pooled data on 8,147 women with invasive epithelial ovarian cancer from the Ovarian Cancer Association Consortium. The prediagnosis inflammation-related exposures of interest included alcohol use; aspirin use; other nonsteroidal anti-inflammatory drug use; body mass index; environmental tobacco smoke exposure; history of pelvic inflammatory disease, polycystic ovarian syndrome, and endometriosis; menopausal hormone therapy use; physical inactivity; smoking status; and talc use. Using Cox proportional hazards models, the relationship between each exposure and survival was assessed in 50% of the data. A weighted inflammation-related risk score (IRRS) was developed, and its association with survival was assessed using Cox proportional hazards models in the remaining 50% of the data. RESULTS: There was a statistically significant trend of increasing risk of death per quartile of the IRRS [HR = 1.09; 95% confidence interval (CI), 1.03-1.14]. Women in the upper quartile of the IRRS had a 31% higher death rate compared with the lowest quartile (95% CI, 1.11-1.54). CONCLUSIONS: A higher prediagnosis IRRS was associated with an increased mortality risk after an ovarian cancer diagnosis. Further investigation is warranted to evaluate whether postdiagnosis exposures are also associated with survival. IMPACT: Given that pre- and postdiagnosis exposures are often correlated and many are modifiable, our study results can ultimately motivate the development of behavioral recommendations to enhance survival among patients with ovarian cancer.

Authors:

KK Brieger, MT Phung, B Mukherjee, KM Bakulski, H Anton-Culver, EV Bandera, DDL Bowtell, DW Cramer, A DeFazio, JA Doherty, S Fereday, RT Fortner, A Gentry-Maharaj, EL Goode, MT Goodman, HR Harris, K Matsuo, U Menon, F Modugno, KB Moysich, B Qin, SJ Ramus, HA Risch, MA Rossing, JM Schildkraut, B Trabert, RA Vierkant, SJ Winham, N Wentzensen, AH Wu, A Ziogas, L Khoja, KR Cho, K McLean, J Richardson, B Grout, A Chase, CM Deurloo, K Odunsi, BH Nelson, JD Brenton, KL Terry, PDP Pharoah, A Berchuck, GE Hanley, PM Webb, MC Pike, CL Pearce, Ovarian Cancer Association Consortium

Journal:

Cancer Epidemiol Biomarkers Prev

Citation info:

31(2):443-452

Publication date:

1st Feb 2022

Full text

DOI